Skip to main content
Premium Trial:

Request an Annual Quote

Test of the China Initiative

Science writes that the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

That program aimed to sniff out instance of economic espionage and research theft in the US by China, but as Science notes, most of nearly two dozen researchers ensnared by the initiative's investigations were not charged with espionage or intellectual property theft. Lieber, for instance, was charged in January 2020 with making false claims about funding he received from China's Thousand Talents Program. Similarly, Anming Hu, a nanotechnology researcher whose case was the first to go to court, was charged with wire fraud and making false statements — charges of which he was acquitted.

Lieber, who has pleaded not guilty, is the next researcher whose case is to head to trial according to Science. It adds that court watchers are wondering how the trial will play out amid increasing calls for the China Initiative to be curbed or even eliminated. Science adds that critics have argued that the errors uncovered in most of the cases should lead to civil or administrative penalties.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.